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AIM: Behc ¸et’s disease (BD) is an inflammatory vascu-
litis with immunologic, endothelial and neutrophil
alterations. Adenosine deaminase (AD) is a marker of
T-cell activation and is related to the production of
reactive oxygen species by neutrophils with the
production of NO
+, O
+ 
2 ; H2O2 and OH
+. We reported
increased tumour necrosis factor-a, soluble interleu-
kin-2 receptor, interleukin-6, interleukin-8 and NO
+
in active BD. As there is a relation between cytokines,
T cells and oxidative stress in inflammatory diseases,
this study further evaluated: (1) plasma AD activity
and its correlation with acute phase reactants; (2)
thiobarbituric acid-reactive substances (TBARS) as an
indicator for lipid peroxidation; and (3) antioxidant
enzymes superoxide dismutase (SOD), glutathione
peroxidase (GSHPx) and catalase in patients with
BD. The effect of disease activity and correlations
between the measured parameters were explored.
Methods: A total of 35 active (n/17) or inactive (n/
18) patients with BD (16 men, 19 women) satisfying
International Study Group criteria, and 20 age-
matched and sex-matched controls (nine men, 11
women) were included in this cross-sectional case 
/
control study. AD and TBARS were measured in
plasma, catalase in red blood cells (RBC), and SOD
and GSHPx in both plasma and RBC in both groups.
Acute phase reactants (a1-antitrypsin, a2-macroglobu-
lin, neutrophils, erythrocyte sedimentation rate)
were used to classify patients as active or inactive.
Results: Plasma AD (mean9 /standard error of the
mean, 36.19 /0.7 U/l) and TBARS (4.29 /0.1 nmol/ml)
levels were significantly (for each, pB/0.001) higher
in BD than in controls (24.19 /0.8 U/l and 1.69 /0.1
nmol/ml, respectively). RBC catalase activity was
significantly (pB/0.001) lower in BD than in controls
(120.99 /3.8 versus 160.39 /4.1 k/g haemoglobin). SOD
and GSHPx activities were significantly lower in both
plasma and erythrocytes of patients with BD than in
controls (plasma SOD, 442.49 /8.6 versus 636.49 /9.2
U/ml, pB/0.001; RBC SOD, 3719.29 /66.0 versus
4849.79 /49.0 U/g haemoglobin, p B/0.001; plasma
GSHPx, 73.19 /1.5 versus 90.69 /2.9 U/ml, pB/0.001;
RBC GSHPx, 600.79 /8.0 versus 670.69 /10.1 U/g
haemoglobin, pB/0.001). Active BD patients had
significantly lower antioxidant enzymes (except
RBC catalase) and higher AD and TBARS levels than
inactive subjects (for each, pB/0.01). When consider-
ing all BD patients, a significant positive correlation
was present between AD and TBARS (pB/0.001)
whereas both AD and TBARS were negatively corre-
lated with antioxidant enzymes (for each, pB/0.05).
Conclusions: AD and lipid peroxidation are increased
and associated with defective antioxidants in BD,
suggesting interactions between activated T cells and
neutrophil hyperfunction. Measures of pro-oxidative
stress and antioxidative defence with AD activity as
an indicator of T-cell activation can be considered as
significant supportive diagnostic indicators, espe-
cially in active disease. In addition, strengthening
the antioxidant defence may contribute to treatment
modalities.
Key words: Adenosine deaminase, Behc ¸et’s disease, Cat-
alase, Free radical, Glutathione peroxidase, Superoxide
dismutase, Thiobarbituric acid-reactive substances
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107Introduction
Adenosine deaminase (AD) is an enzyme that is
required for lymphocyte proliferation, maturation
and differentiation with detected biologic activity,
particularly in T cells.
1 AD activity is known to be
increased in inflammatory diseases characterised by
T-cell activation and proliferation. Therefore, AD is
considered a marker of T-cell activation.
2 In addition,
overproduction of reactive oxygen species (ROS)
including hydrogen peroxide (H2O2), superoxide
anion (O
+ 
2 ); nitric oxide (NO
+) and singlet oxygen
(
1O2) creates a condition known as oxidative stress,
resulting in the amplification of the inflammatory
response.
3 Self-propagating lipid peroxidation (LPO)
against membrane lipids begins and endothelial
dysfunction ensues. Endogenous free radical scaven-
ging enzymes (FRSEs) such as superoxide dismutase
(SOD), glutathione peroxidase (GSHPx) and catalase
are, however, involved in the disposal of O
+ 
2 and
H2O2. First, SOD catalyses the dismutation of O
+ 
2 to
H2O2 and molecular oxygen (O2), resulting in
selective O
+ 
2 scavenging. Then, GSHPx and catalase
independently decompose H2O2 to H2O.
4 When free
radicals are generated in excess or when FRSEs are
defective, however, H2O2 is reduced into hydroxyl
radical (OH
+), which is one of the highly reactive
ROS.
Behc ¸et’s disease (BD), first described by the
Turkish Dermatologist Prof. Dr Hulusi Behc ¸et in
1937
5 as orogenital ulcerations with hypopyon uvei-
tis, is a chronic relapsing inflammatory vasculitis
characterised by endothelial dysfunction, neutrophil
hyperfunction and ROS overproduction.
6 It occurs
endemically in Turkey, the Middle East and Japan,
with a 3:2 male to female ratio, the population
derived from the ancient Silk Road.
6 It begins
between the second and fourth decades of life
(range, 0 /72 years) and affects every tissue in the
body including the cornea,
7 inner ear,
8 kidney,
9 and
the lung.
10 Although several aetiopathogenetic mole-
cules have been implicated,
6,11 the intermittent
nature and the lack of consistent response to therapy
make the underlying aetiology difficult to define.
Diagnosis is usually based on its clinical presentations
and there is, however, no any specific laboratory test
to make the diagnosis. It is therefore of great
importance to determine the factor(s) that may lead
to disease and to find some rapid and useful
laboratory test(s) for the diagnosis of this unique
disorder.
We demonstrated that adrenomedullin,
12 leptin,
13
homocysteine and endothelin-1
14 might participate in
the aetiopathogenesis of BD. In addition, we re-
ported that pro-inflammatory cytokines
15 tumour
necrosis factor (TNF)-a, soluble interleukin-2 recep-
tor (sIL-2R), interleukin (IL)-6 (inducers of NO
+
synthesis), chemokine IL-8, and NO
+16 (most abun-
dant free oxygen radical in the body) were increased
in patients with BD, suggesting a new activity marker
for NO
+. To test the inter-relationship between T-cell
hyperfunction, oxidative stress and ROS overproduc-
tion in inflammatory BD, this study further investi-
gated: (1) the activity of AD in plasma as an index of
T-lymphocyte hyperfunction; (2) the catalytic activity
of endogenous antioxidant FRSEs SOD and GSHPx in
both plasma and erythrocytes; (3) the catalytic
activity of catalase in erythrocytes; and (4) the levels
of thiobarbituric acid-reactive substances (TBARS) in
plasma as an indicator for LPO status in patients with
BD. We also assessed the effect of disease activity and
evaluated the possible correlations between acute
phase reactants, AD, LPO and FRSEs.
Materials and methods
Patients, controls, and disease classification
Informed consent was obtained from all participants
in both groups. Patients with BD were recruited from
the Departments of Ophthalmology and Dermatol-
ogy (Behc ¸et’s services) at the university hospital.
Thirty-five patients with active or inactive BD (16
men, 19 women) with a mean age of 32.6 years, and
20 age-matched and sex-matched hospital-based
healthy volunteers (nine men, 11 women) with a
mean age of 31.7 years from a similar ethnic origin
were enrolled in this cross-sectional investigation.
Patients with BD had to fulfil the International Study
Group criteria for the diagnosis of BD
17 (Table 1).
Exclusion criteria in both groups were hepatic or
renal diseases, alcoholics, diabetes, essential hyper-
tension, pregnancy, malignancy or another chronic
inflammatory disease and the history of recent
medications.
Active (n /17) and inactive (n /18) BD patients
were classified by both laboratory and clinical find-
ings because there was no clinically acceptable
scoring system or standard laboratory screening
profile to define the severity of BD. In laboratory
assessment, neutrophil count, erythrocyte sedimenta-
tion rate (ESR), and acute phase reactants (a1-
antitrypsin and a2-macroglobulin levels) were mea-
sured and used as the indicators for disease activ-
ity.
12,15,16 Patients’ details were obtained from case
notes, and ocular examinations were performed by
two experienced ophthalmologist using a standard
procedure. In clinical evaluation, worsening of clin-
ical symptoms at the time of the present investigation
with having at least three of the four major symptoms
(oral aphthae, genital ulceration, cutaneous lesions,
and anterior and/or posterior uveitis) were consid-
ered to be the active period of the disease. The
inactive patients had no any symptoms and signs of
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108 Mediators of Inflammation Vol 12  2003Table 1. Diagnostic criteria and clinical features of patients with active or inactive Behc ¸et’s disease (International Study Group criteria for the diagnosis of Behc ¸et’s disease*)
17
Patient
number
Age (years)/
gender
Course (years) Oral
aphthae
Genital
ulcers
Ocular
lesions
$
Pathergy
test
%
Thrombophlebitis Erythema
nodosum
Acneiform
nodules
Pseufofolliculitis
1
§ 20/male 1   /  /   /   /  /  /  /   /
2
§ 40/female 14   /   /   /  /  /   /   /  /
3
§ 27/male 3   /   /   /   /  /  /  /   /
4
§ 30/male 3   /   /   /  /  /  /   /   /
5
§ 48/female 7   /  /   /   /   /  /   /  /
6
§ 34/male 5   /   /  /   /  /   /  /   /
7
§ 35/male 8   /   /  /  /   /  /   /  /
8
§ 37/male 12   /   /   /  /  /  /   /  /
9
§ 35/female 13   /   /  /   /  /  /   /   /
10
§ 25/male 6   /   /   /  /  /  /  /  /
11
§ 43/female 24   /   /  /   /   /  /   /   /
12
§ 50/female 29   /   /   /   /  /   /  /  /
13
§ 30/female 3   /   /   /  /  /  /  /   /
14
§ 18/female 1   /   /  /  /  /   /  /   /
15
§ 33/male 8   /  /  /   /  /   /   /  /
16
§ 29/female 5   /  /   /   /  /  /  /   /
17
§ 30/female 4   /   /   /  /   /  /   /  /
18 50/female 27   /   /   /  /  /   /   /  /
19 28/male 6   /   /  /   /  /  /   /  /
20 31/female 4   /   /  /   /  /  /   /   /
21 31/male 11   /   /  /  /  /  /   /   /
22 32/female 4   /   /  /  /   /  /   /  /
23 33/female 6   /   /   /   /  /  /  /  /
24 32/male 13   /   /  /   /   /  /   /   /
25 20/female 4   /   /   /  /  /  /   /  /
26 42/female 17   /   /   /   /  /  /  /   /
27 25/female 4   /   /   /  /   /  /  /   /
28 32/female 9   /   /   /   /  /  /   /  /
29 33/male 7   /  /  /   /  /   /   /   /
30 52/female 21   /   /   /  /  /  /   /  /
31 35/male 5   /   /  /   /  /  /   /   /
32 38/male 11   /   /   /   /   /  /  /   /
33 19/female 3   /   /  /  /  /  /   /   /
34 22/male 2   /   /  /  /  /  /   /   /
35 25/male 2   /   /   /   /  /  /  /   /
*Oral aphthae plus two of the following criteria: genital ulcers, ocular lesions, cutaneous lesions, pathergy test positivity.
$Unilateral or bilateral (anterior and/or posterior) uveitis.
%Observation of a pustular lesion by physician at 24 /48 h.
§Active patients with Behc ¸et’s disease.
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9disease activity at least 4 weeks before admission.
The diagnosis of uveitis was made according to the
International Uveitis Study Group.
18
Sample collection
This was a double-blind study. Therefore, both
laboratory personnel and physicians taking the blood
were blinded to the group of the subject. In both
groups, whole-blood samples were taken by veni-
puncture from an antecubital peripheral vein using a
25-gauge needle, avoiding haemolysis, into evacu-
ated Vacutainer plain tubes with ethylenediamine
tetraacetic acid during the resting position in the
morning hours (8:00 /10:00 h) after an overnight fast
and 30 min of supine rest. The same procedures were
applied to all BD patients and control subjects.
Standard blood screening parameters (red blood
cell (RBC) count, platelet count, sodium, potassium,
blood urea nitrogen (BUN), creatinine, aspartate, and
alanine aminotransferase) and routine urine analyses
had to be within normal limits. These parameters
were tested by a routine autoanalyser (Coulter-STKS;
Coulter Electronics, Luton, UK).
None of the patients with BD and the control
volunteers received any systemic or topical medica-
tion on admission at least 1 month prior to blood
collection. The samples were centrifuged at 3000 /g
for 10 min at 48C, and the harvested plasma was
collected, subdivided and transferred into polyethy-
lene tubes. Subdivided samples were immediately
frozen at   /708C to be used in the assay of plasma
SOD and GSHPx, AD and TBARS. The buffy coat on
the erythrocyte sediment was carefully separated.
The erythrocytes were subsequently washed twice
with two volumes of 0.9% sodium chloride solution
to remove the plasma remnants. Following this, the
erythrocytes were haemolysed with two-fold vo-
lumes of ice-cold distilled water. After centrifugation
(5000 /g, 10 min, 48C) the supernatant was sub-
divided and transferred into polyethylene tubes and
frozen at   /708C to be used in the assay of RBC SOD,
GSHPx and catalase activities. The haemoglobin
(Hb) content was also measured, and enzyme activity
was determined per milligram of Hb.
Neutrophil count, ESR, a1-antitrypsin and a2-
macroglobulin assay for disease activity
Neutrophil counting was performed by the same
automated blood counter as earlier. a1-Antitrypsin
and a2-macroglobulin levels were measured by the
Behring nephelometer 100 analyser (Dade Behring,
Messer Griesheim, Frankfurt, Germany). The ESR was
determined by the classical Westergren method.
Erythrocyte catalase assay
The activity of catalase in subdivided supernatant was
measured according to the method of Aebi
19 by
monitoring the initial rate of disappearance of H2O2
(initial concentration, 10 mM) at 240 nm (e /0.041
mmol
 1 /1 /cm
 1) in a cuvette containing 10.5
mM H2O2 in 1 ml of 50 mM phosphate buffer (pH 7,
258C), in a spectrophotometer. The result was
reported as a constant rate per second per gram of
Hb (k/g Hb).
Erythrocyte and plasma SOD assay
The activity of SOD in subdivided supernatant and
plasma was measured according to the method of
Sun et al.
20,21 by determining the inhibition of
nitroblue tetrazolium reduction, with xanthine /
xanthine oxidase used as an O
+ 
2 generator. Activity
was assessed in the ethanol phase of the lysate after
1.0 ml of ethanol/chloroform mixture (5/3, v/v) was
added to the same volume of the haemolysate and
centrifuged. One unit of SOD is defined as the
amount of SOD that inhibits the rate of nitroblue
tetrazolium reduction by 50%. Results were defined
as units per millilitre of plasma or units per gram of
Hb (U/ml plasma or U/g Hb).
Erythrocyte and plasma GSHPx assay
The activity of GSHPx in subdivided supernatant and
plasma was measured according to the method of
Paglia and Valentine.
22 Enzyme activity was deter-
mined from the oxidation of reduced NADPH in the
presence of H2O2 used as substrate. The decrease in
concentration of NADPH was monitored and re-
corded at 340 nm in a mixture containing reducted
glutathione and glutathione reductase (pH 7.8, 258C).
Enzyme units were defined as the number of micro-
moles of NADPH oxidised per minute. Results were
defined as international units per millilitre of plasma
or units per gram of Hb (U/ml plasma or U/g Hb).
Plasma TBARS assay for LPO
LPO is frequently investigated in biomedical research,
and the assays for TBARS are much more widely used
than any other index of LPO in biological samples.
23
Thiobarbituric acid reacts with LPO aldehydes, such
as malondialdehyde (MDA). Therefore, assessment of
TBARS is a useful indice of oxidative deterioration
and LPO determination in body fluids.
2 The level of
plasma TBARS was estimated according to the
method described by Wasowicz et al.
24 The principal
of the method is based on the coupling of TBARS
with thiobarbituric acid. All measurements (standards
and samples) were done at the upper n-butanol
phase of the reaction mixture. In brief, 50 ml of
K. Erkilic ¸ et al.
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standard solution was introduced into 10 ml glass
tubes containing 1 ml of distilled water. After addition
of 1 ml of the solution containing 29 mmol/l of
TBARS in acetic acid and mixing, the samples were
placed in a water bath and heated for 1 h at 95 /
1008C. After the samples were cooled, 25 ml of 5 mol/l
HCI was added, and the reaction mixture was
extracted by agitation for 5 min with 3.5 ml of n-
butanol. The butanol phase was separated by cen-
trifugation at 1500 /g for 10 min. The butanol extract
was measured with a spectrofluorometer (F-4010
fluorescence spectrophotometer; Hitachi, Tokyo, Ja-
pan) at wavelengths of 525 nm for excitation. The
calibration curve was prepared with MDA standards
of 0 /10 mmol/l. Intra-assay and inter-assay CVs were
3.5% and 6%, respectively. Results were expressed as
nanomoles per millilitre.
Plasma AD assay
The activity of AD in plasma was measured according
to the method of Giusti.
25 Optical density was
measured spectrophotometrically at 265 nm in an
assay mixture (final volume, 2 ml) containing 0.025
nM adenosine, 10 nM Tris /HCl (pH 7.4), 0.15 M
sodium chloride, 1.25% glycerol, and 0.02 ml of
serum. One unit of activity represents the deamina-
tion of 1 mM adenosine/min at 378C temperature and
is expressed as units per litre (U/l).
Calculations and statistics
Kruskal /Wallis variance analysis or the Mann /Whit-
ney U-test was used as indicated for statistical
pairwise comparison of groups, and results were
expressed as mean9 /standard error. Spearman’s cor-
relation coefficients (r) were performed to determine
whether there is any correlation between antioxidant
enzymes and LPO or AD activity. Two-tailed signifi-
cance values were used and p B/0.05 was considered
significant. Statistical analysis was performed with
Statistical Package for the Social Sciences for Win-
dows (Release 7.5; SPSS/PC  / Inc., Chicago, IL, USA).
Results
Oral aphthae was present in all BD patients (100%)
(Table 1). Twenty patients (58.8%) had a variety of
ocular inflammation (anterior iridocyclitis or hypop-
yon uveitis, posterior retinal vasculitis or vitreal cells,
or panuveitis), and 32 of 34 patients (94.1%) had
various cutaneous lesions (acneiform nodules,
thrombophlebitis, erythema nodosum, pseudofolli-
culitis). Genital ulcerations were described in 30
patients (88.2%), and the pathergy test (observation
a pustular lesion after needlestick by a physician at
24 /48 h) was positive in 19 patients (55.9%). Addi-
tional findings were articular symptoms and signs
(arthralgia, arthritis, sacroiliitis) in 18 patients
(82.3%), neurological symptoms (migraine-like head-
ache) in seven patients (20.5%), and gastrointestinal
system symptoms and signs (appendicitis like pain,
melena) in five patients (14.7%).
The age and sex ratio was similar (p /0.05)
between groups. Active BD patients had significantly
higher levels for acute-phase reactants than patients
in the inactive stage (pB/0.001) or control subjects
(pB/0.001) (Table 2). Mean RBC catalase activity was
significantly (pB/0.001) lower in BD patients
(120.99 /3.8 k/g Hb) than controls (160.39 /4.1 k/g
Hb). Mean plasma and RBC activities of SOD and
GSHPx were significantly lower in patients with BD
than in control subjects (plasma SOD, 442.49 /8.6
versus 636.49 /9.2 U/ml, pB/0.001; RBC SOD,
3719.29 /66.0 versus 4849.79 /49.0 U/g Hb, pB/
0.001; plasma GSHPx, 73.19 /1.5 versus 90.69 /2.9
U/ml, pB/0.001; RBC GSHPx, 600.79 /8.0 versus
670.69 /10.1 U/g Hb, pB/0.001). Mean plasma AD
activity was significantly (pB/0.001) higher in pa-
tients than control volunteers (36.19 /0.7 versus
24.19 /0.8 U/l). Plasma TBARS levels in patients and
control subjects were 4.29 /0.1 and 1.69 /0.1 mmol/l,
Table 2. Comparative analysis of acute phase reactants a1-antitrypsin and a2-macroglobulin, erythrocyte sedimentation rate
and polymorphonuclear leukocyte count in patients with active or inactive Behc ¸et’s disease and healthy control volunteers:
statistical analysis
Active patients (n /17)
(8 men, 9 women)
Inactive patients (n /18)
(8 men, 10 women)
Control subjects (n /20)
(9 men, 11 women)
Age* (years) 33.19 /2.1 32.29 /2.1 31.79 /1.8
a1-Antitrypsin (mg/dl) 223.59 /6.7
$ 154.59 /4.8 125.09 /7.8
a2-Macroglobulin (mg/dl) 274.59 /7.8
$ 198.09 /7.3 144.19 /5.6
ESR (mm/h) 43.19 /2.0
$ 21.29 /1.2 10.99 /0.6
PMNL count (/ml) 5.99 /0.2
$ 3.49 /0.1 2.59 /0.1
Data presented as mean9 /standard error of mean. n, number of subjects.
* Mean age was similar between groups by Kruskal /Wallis variance analysis (for each, p /0.05).
$ Significantly higher than inactive patients and control subjects by Mann /Whitney U-test or Kruskal /Wallis variance analysis (for each, pB/
0.001).
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0.001; Table 3).
In correlation analysis, there was a significant
positive correlation between plasma AD activity and
TBARS levels, and significant but negative correlation
between AD and antioxidant enzymes (Table 4). In
addition, plasma TBARS levels were also negatively
correlated with antioxidant enzymes. Active patients
had significantly higher plasma AD and TBARS
activities over inactive patients (for each, pB/0.001).
In addition, both ESR and neutrophil count were
positively correlated with AD and LPO activities (for
each, pB/0.001; Table 5).
Discussion
Immune system dysregulation, T-cell and B-cell
activation, immunoactive cell infiltration into the
affected regions followed by accelerated neutrophil
chemotaxis and phagocytosis have been implicated
in BD.
6 Increased production of the immunoglobu-
lins,
6 pro-inflammatory cytokines,
15 NO
+16 and
O
+ 
2
/
26 as well as a change in lipids and lipoprotein
metabolism
27 have also been demonstrated, support-
ing the possibility that BD is an immunologic
disorder. Ocular involvement occurs in 50 /70% of
patients and is characterised by periphlebitis, periar-
Table 3. Adenosine deaminase, thiobarbituric acid-reactive substances, superoxide dismutase, glutathione peroxidase and
catalase activities in red blood cells or plasma of patients with Behc ¸et’s disease and healthy control volunteers: statistical
analysis
Active patients (n /17)
(8 men, 9 women)
Inactive patients (n /18)
(8 men, 10 women)
Control subjects (n /20)
(9 men, 11 women)
RBC catalase (k/g Hb) 115.09 /5.4
$ 126.59 /5.3
$ 160.39 /4.1
Plasma SOD (U/ml) 405.79 /8.4
$§ 477.09 /9.0
$ 636.49 /9.2
RBC SOD (U/g Hb) 3392.19 /65.1
$§ 4028.19 /40.3
$ 4849.79 /49.0
Plasma GSHPx (U/ml) 70.59 /2.8
$§ 75.69 /0.8
$ 90.69 /2.9
RBC GSHPx (U/g Hb) 559.19 /5.6
$§ 640.09 /5.9
$ 670.69 /10.1
Plasma AD (U/l) 39.89 /0.6
%’ 32.59 /0.4
% 24.19 /0.8
Plasma TBARS (nmol/ml) 4.49 /0.1
% 4.09 /0.1
% 1.69 /0.1
Data presented as mean9 /standard error of mean. n, number of subjects.
*Mean age and gender ratio was similar between groups (p /0.05).
$Significantly lower than control subjects by Mann /Whitney U-test or Kruskal /Wallis variance analysis (for each, pB/0.001).
%Significantly higher than control subjects by Mann /Whitney U-test or Kruskal /Wallis variance analysis (for each, pB/0.001).
§Significantly lower than inactive BD patients by Mann /Whitney U-test (for each, pB/0.001).
’Significantly higher than inactive BD patients by Mann /Whitney U-test (for AD, pB/0.001; for TBARS, p /0.023).
Table 5. Correlations between erythrocyte sedimentation rate and polymorphonuclear leukocyte count with adenosine
deaminase and thiobarbituric acid-reactive substances in patients with Behc ¸et’s disease
Behc ¸et’s patients (n /35) Control subjects (n /20)
r value p value r value p value
ESR /AD 0.950 B/0.001   /0.164 NS
PMNLs /AD 0.944 B/0.001   /0.227 NS
ESR /TBARS 0.567 B/0.001 0.168 NS
PMNLs /TBARS 0.564 B/0.001 0.028 NS
n, Number of subjects; NS, not significant.
Table 4. Correlation analysis between superoxide dismutase, glutathione peroxidase, catalase, adenosine deaminase and
thiobarbituric acid-reactive substances in patients with Behc ¸et’s disease
Behc ¸et’s patients (n /35) Control subjects (n /20)
r value p value r value p value
Plasma SOD /AD   /0.855 B/0.001 0.364 NS
RBC SOD /AD   /0.884 B/0.001   /0.141 NS
Plasma GSHPx /AD   /0.375 0.026 0.337 NS
RBC GSHPx /AD   /0.893 B/0.001 0.071 NS
RBC catalase /AD   /0.498 0.002 0.160 NS
AD /TBARS 0.639 B/0.001 0.215 NS
n, Number of subjects; NS, not significant.
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blindness despite vigorous treatment.
14 Likewise,
systemic venous thrombogenesis occurs in 40%
28 of
cases as a result of endothelial dysfunction
29 and
multifocal necrotising vasculitis with lymphocytic
infiltration.
6
Free radicals are derived from the metabolism of
free fatty acids and arachidonic acid, and from an
univalent sequential reduction of O2 with detrimental
effects at both cellular and molecular levels.
30 Ery-
throcytes are particularly sensitive to oxidative stress
and are supplied with protective defence system in
order to counteract excess ROS. Therefore, free
radicals are scavenged by high (SOD, GSHPx,
catalase) and low (ascorbic acid, a-tocopherol)
molecular weight antioxidants.
31 On the other hand,
if SOD and GSHPx activities decrease concomitantly,
O
+ 
2 and H2O2 intermediate free radicals then
accumulate and undergo the Fenton reaction. This
generates the hydroxyl radical (OH
+) and LPO of
membrane lipids, proteins and nucleic acids, and
causes the deterioration of cell transport and energy
metabolism with protein and enzyme degradation,
endothelial dysfunction, tissue oedema, DNA damage
and eventually cellular death.
32
Excessively produced free radicals by polymor-
phonuclear leukocytes (PMNLs) have been suggested
to mediate tissue injury in BD.
6 Indeed, excess H2O2-
induced MDA production with increased macro-
phage activity has been demonstrated both in vivo
and in vitro, suggesting increased neutrophil-derived
ROS production in patients with BD.
33 In the present
study, lower endogenous FRSEs (here represented by
decreased SOD, GSHPx and catalase activities) may
result in insufficient O
+ 
2 and H2O2 removal and,
therefore, limited enzymatic adaptation to ROS in BD.
In other words, two-fold to three-fold increased
TBARS with a concomitant reduction of FRSEs sup-
port the presence of circulating pro-oxidants with cell
damaging effects, making the tissues more vulnerable
to toxic effects of ROS in BD. TBARS levels in the
present study showed the strongest correlation with
AD levels followed by ESR and PMNLs, suggesting
accelerated cellular peroxidative reactions in active
BD. Indeed, the present study further demonstrated
that SOD as well as GSHPx activities declined during
disease activity, causing the possible deterioration of
H2O2 elimination and excess ROS formation in
exacerbation period. Therefore, the results of the
current study supported our previous reports and
suggested a higher need for antioxidants in such
patients, especially in active disease.
AD is distributed throughout the human body and
its physiological activity is found in T cells, where its
level is five-fold to 20-fold higher than B cells.
1 It is
required for lymphocyte proliferation and matura-
tion, and raised AD activity is found where cell-
mediated immunity is stimulated. AD activity is a
marker of activated neutrophil functions with che-
motaxis, phagocytosis and O
+ 
2 production, demon-
strating the possible source of ROS. We found higher
AD activity in Behc ¸et’s patients than controls. This
was to be expected, since increased cellular and
humoral activities as well as the infiltration of T cells
into the affected regions followed by a second phase
of neutrophil chemotaxis are well-defined phenom-
ena in patients with BD.
34 Indeed, we found that AD
activity was correlated not only with TBARS levels,
but also with acute phase reactants ESR and PMNLs.
Therefore, this suggested that T-cell activation and
neutrophil hyperfunction with excessive free radical
insult were associated with increased LPO in BD.
Since activated T lymphocytes cause neutrophil
activation, and neutrophils are one of the main ROS-
generation systems in BD patients, increased produc-
tion of AD and TBARS confirms the presence of an
inter-relationship between T cells and neutrophils in
such patients. Moreover, the present study demon-
strated that decreased FRSE activities in both plasma
and erythrocyte were negatively correlated with
increased AD and LPO in BD. That is, lymphocyte
function increases in accordance with ROS produc-
tion and LPO, suggesting a possible new activity
marker for AD in BD. Therefore, the current hypoth-
esis is that infiltration of T cells into the vascular wall
followed by a neutrophil chemotaxis are associated
with central changes in circulating neutrophils, with
activation of these cells in BD. Activated T lympho-
cytes may produce inflammatory cytokines through
heat shock proteins in active BD, leading to macro-
phage and neutrophil activations with excessive ROS
generation. Indeed, this study showed that active BD
patients had higher AD activity than inactive patients.
Therefore, since the increase in AD activity reflects
the enhanced functions of immunocompetent cells in
response to inflammatory stimuli, it may be used as a
simple biochemical test for rapid preliminary evalua-
tion of the severity of disease and immune perfor-
mance in BD. In other words, the clinical inference is
that measurement and monitoring of AD may be
valuable in the management of BD patients both in
active and inactive periods.
The inflammatory process is a serious risk factor
for atherosclerosis,
35 one of the most common
features of BD.
36 In addition, a higher lipoprotein
level has been shown in BD, which is correlated with
acute phase reactants such as ESR, PMNLs and PMNL
elastase activities,
37 contributing a risk factor in the
development of thrombogenic and atherosclerotic
complications in such patients. Atherosclerosis, in
turn, leads to the synthesis of inducible nitric oxide
synthase (iNOS), the enzyme that is responsible for
NO
+ and O
+ 
2 generation in smooth muscle cells,
macrophages and neutrophils within the vascular
wall.
38 Actually, NO
+ toxicity is now considered to be
mainly mediated by its products, the peroxynitrite
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+, mediating tissue injury
and LPO.
39,40
Fujita et al.
26 demonstrated the generation of
superoxide radical by neutrophils in BD. Kose et
al.
33 evaluated the effect of an antioxidant on
lipoperoxidation induced by H2O2 in erythrocytes
of BD patients, which is independently destroyed by
catalase and GSHPx. Important in this respect is our
report demonstrating increased NO
+ production
16
(the most abundant free radical in the body) during
the course of BD, especially in exacerbation period,
which was supported by various investigations.
14,41,42
In addition, Yilmaz et al.
43 showed elevated aqueous
humor NO
+ levels in BD patients afterwards. More-
over, our finding that found homocysteinemia in BD
patients was supported by two independent re-
ports.
44,45 Furthermore, we have recently demon-
strated that pro-inflammatory cytokines including
TNF-a, sIL-2R, IL-6, and chemokine IL-8 are increased
in active BD.
15 Since these cytokines are known to
activate neutrophil function and induce the produc-
tion of iNOS
40 (thus NO
+) by the upregulation of
endothelial cells, the interplay between AD, O
+ 
2 ;
NO
+ and ONOO
  in the vascular wall of BD is likely
to cause antioxidant enzyme depletion and, there-
fore, oxidative LPO found in the present study. In
addition, this observation was possibly due not only
to endothelial cells, but also to PMNL and macro-
phages found in inflammation because these cells
were also known to be involved in the pathogenesis
of BD.
6 If all the previous and present findings are
hypothetically incorporated in the well-known enzy-
matic ROS production schema, Fig. 1 can be obtained
and the possible aetiopathogenic inter-relationship
between the oxidative stress and antioxidant defence
in such patients can clearly be observed. Based on
the presented evidence, it is therefore conceivable
that decreased SOD and GSHPx activities found in
this study possibly pair with the increased cytokines
and NO
+, resulting in excessive pro-oxidant produc-
tion with mitochondrial respiratory enzyme inhibi-
tion in BD. Furthermore, the observation that
lowered FRSEs in active BD are in line with this
suggestion, indicating that the neutrophils of active
patients are much more vulnerable to oxidative injury
than inactive patients.
FIG. 1. Schematic representation of enzymatic ROS production, antioxidant system and lipid peroxidation in oxidative stress.
Molecular oxygen can be reduced by various enzymatic reactions, and the formed superoxide anion (O+ 
2 ) is reduced into
hydrogen peroxide (H2O2) by superoxide dismutase (SOD). H2O2 is independently destroyed by catalase and glutathione
peroxidase (GSHPx) in the presence of reduced glutathione (GSH). When they are produced in excess, a Fenton reaction
develops and H2O2 is reduced into hydroxyl radical (OH
+), the most potent ROS. Nitric oxide synthase (NOS), which produces
the most abundant free radical NO
+, can also contribute to oxidative stress. The short-lived NO
+ reacts with O+ 
2 ; leading to
peroxynitrite anion (ONOO
 ) production, which is a potent and powerful long-lived free oxygen radical. ONOO
  further
decomposes into OH
+. The ﬁgure also shows our previous ﬁndings that could be incorporated into this ﬁgure by means of
hypothetical aetiopathogenic mechanisms of BD. GSSG, oxidised glutathione; GSHRed, glutathione reductase; PUFAs,
polyunsaturated fatty acids.
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previous studies and demonstrated not only the
particular role of AD and LPO in BD, but also
emphasised lowered endogenous FRSEs in both
plasma and erythrocytes in such patients. Indeed, a
significant but negative correlation between antiox-
idant enzymes and increased AD or LPO was found,
causing cellular peroxidative reactions during the
disease process, especially in active disease. Ameli-
oration of some clinical manifestations may therefore
be envisaged by targeting ROS with the supplemen-
tation of dietary or pharmacological antioxidants
(vitamins C and E), which are capable of breaking
the LPO chain reaction in cell membranes, thus
reducing oxidative stress and improving vascular
function. In addition, it would be helpful to investi-
gate the prognostic value of changes of these pro-
oxidative and/or antioxidative parameters during the
course of therapy and to assess whether pretreatment
with ROS scavengers reduces tissue damage in BD.
These changes can provide insights into pathophy-
siology and, in a clinical situation, may be used to
assess the severity of an injury. Furthermore, it
appears that plasma AD activity can be used for the
diagnosis of BD to support clinical findings and as an
index for disease activity. It can also be used during
the follow-up period of the patients as well as to
monitor the effect of the treatment, if further studies
demonstrate its sensitivity or specificity.
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